A Phase I/IIa Study of BMS-986148, a Mesothelin Directed Antibody Drug Conjugate, in Subjects With Select Advanced Solid Tumors

Trial Profile

A Phase I/IIa Study of BMS-986148, a Mesothelin Directed Antibody Drug Conjugate, in Subjects With Select Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs BMS 986148 (Primary) ; Nivolumab
  • Indications Gastric cancer; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 30 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 30 May 2017 Planned primary completion date changed from 15 Apr 2019 to 14 Jun 2021.
    • 15 May 2017 Planned End Date changed from 1 Dec 2019 to 29 Aug 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top